We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-0.49%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$312M
AUM Growth
+$302M
Cap. Flow
+$306M
Cap. Flow %
98.25%
Top 10 Hldgs %
48.33%
Holding
84
New
6
Increased
59
Reduced
1
Closed
18

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$30.2M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$25.2M
3
INCY icon
Incyte
INCY
+$20M
4
ALKS icon
Alkermes
ALKS
+$15.4M
5
GILD icon
Gilead Sciences
GILD
+$12.6M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.77M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$121K
3
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$107K
4
FOLD
Amicus Therapeutics
FOLD
+$94.6K
5
IMVT icon
Immunovant
IMVT
+$60K

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
76
Prothena Corp
PRTA
$467M
– –
-407
Closed -$15K
PTGX icon
77
Protagonist Therapeutics
PTGX
$9.67B
– –
-128
Closed -$16.2K
SWTX
78
DELISTED
SpringWorks Therapeutics
SWTX
– –
-401
Closed -$16.3K
TSVT
79
DELISTED
2seventy bio
TSVT
– –
-48
Closed -$3.67K
GMDA
80
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-187
Closed -$107K
KRTX
81
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-1,567
Closed -$12.4K
ICPT
82
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-441
Closed -$32K
CCXI
83
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-3,000
Closed -$121K
1 2 3
4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2022 Portfolio in Review

As of Q3 2022, International Biotechnology Trust held 84 positions worth $312M, up 3,153% from $9.59M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

International Biotechnology Trust deployed $306M of net new capital in Q3 2022, opening 6 new positions and adding to 59 existing holdings. Its largest new stake was Viatris: 364,000 shares worth $3.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $1.77M trimmed.

  • International Biotechnology Trust's largest Q3 2022 buy was Viatris: 364,000 shares worth $3.1M.
  • International Biotechnology Trust added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, an estimated $30.2M increase.
  • International Biotechnology Trust's biggest Q3 2022 reduction was Regeneron Pharmaceuticals, cutting an estimated $1.77M.
  • International Biotechnology Trust fully exited ChemoCentryx, Inc. in Q3 2022, selling an estimated $121K.
  • International Biotechnology Trust's ten largest holdings make up 48% of its $312M portfolio in Q3 2022.
  • International Biotechnology Trust opened 6 new positions and closed 18 in Q3 2022.
  • International Biotechnology Trust's portfolio value rose 3,153% quarter-over-quarter to $312M.

Based on International Biotechnology Trust's 13F filing for Q3 2022, filed 8 Nov 2022.